Frequency and features of cardiovascular diseases in spondyloarthritis
- 作者: Samigullina R.1, Mazurov V.1,2, Vasilenko E.2, Trofimov E.1
-
隶属关系:
- North-Western Medical State University named after I.I. Mechnikov
- Saint Petersburg State University
- 期: 卷 3, 编号 4 (2023)
- 页面: 33-44
- 栏目: Original Research
- URL: https://journals.rcsi.science/cardar/article/view/254314
- DOI: https://doi.org/10.17816/cardar624781
- ID: 254314
如何引用文章
详细
BACKGROUND: Group of spondyloarthritis include not only damage of musculoskeletal system, oftenly it’s combination with a variety of comorbid pathologies, primarily involving the cardiovascular system, is characteristic. Given the high importance of early detection, assessment and further prediction of the risks of cardiovascular diseases in this cohort of patients, a competent interpretation of the risks of aggravating cardiovascular diseases and their prevention is one of the priority tasks not only for rheumatologists, but also for specialists in related fields.
AIM: To study the structure of comorbid pathology and assess the frequency of cardiovascular diseases in patients with ankylosing spondylitis, psoriatic arthritis and psoriatic spondyloarthritis, to conduct a comparative analysis of the incidence of cardiovascular comorbidities in different groups of spondyloarthritis.
MATERIALS AND METHODS: The study included 153 patients with a verified diagnosis of spondyloarthritis. Patients were divided into 3 groups depending on the nature of the lesion of the musculoskeletal system: ankylosing spondylitis meeting the modified New York criteria for ankylosing spondylitis (1984) (n = 53), psoriatic arthritis meeting the CASPAR criteria (Classification criteria of Psoriatic Arthritis, 2006) (n = 40) and psoriatic spondylitis simultaneously meeting the modified New York criteria for ankylosing spondylitis and the CASPAR criteria for psoriatic arthritis (n = 60). All patients taken with monoclonal antibodies (inhibitors TNF-alpha).
RESULTS: When studying cardiovascular comorbidity in patients with spondyloarthritis in three groups, arterial hypertension was most common in the ankylosing spondylitis group — 37.7%, in psoriatic arthritis — 62.5%, in the psoriatic spondyloarthritis group — 51.7%, conduction disturbance in ankylosing spondylitis — 28, 3%, in psoriatic arthritis — 17.5%, in the psoriatic spondyloarthritis group — 18.3%, dyslipidemia is significantly more common in the psoriatic arthritis and psoriatic spondyloarthritis groups — 47.5% and 51.7%, respectively, compared with the ankylosing spondylitis group — 18.9%. Along with cardiovascular diseases, endocrine disorders were detected with a high frequency of occurrence: overweight was more common in patients of the psoriatic arthritis and psoriatic spondyloarthritis groups — 35.0 and 38.3%, respectively, significant differences in the incidence of type 2 diabetes mellitus in the three groups has not been identified.
CONCLUSIONS: It is necessary to carry out medical examination in order to identify comorbidities in patients with various forms of spondyloarthritis, in order to determine further tactics of management and correction, depending not only on the activity of the disease, but also taking into account comorbidities.
作者简介
Ruzana Samigullina
North-Western Medical State University named after I.I. Mechnikov
编辑信件的主要联系方式.
Email: dr.samigullina@yandex.ru
ORCID iD: 0000-0002-6341-3334
SPIN 代码: 6590-4637
Scopus 作者 ID: 57220224324
assistant lecturer, North-Western State Medical University named after I.I. Mechnikov
俄罗斯联邦, Saint PetersburgVadim Mazurov
North-Western Medical State University named after I.I. Mechnikov; Saint Petersburg State University
Email: maz.nwgmu@yandex.ru
ORCID iD: 0000-0002-0797-2051
SPIN 代码: 6823-5482
Academician of the Russian Academy of Sciences, MD, Dr. Sci. (Med.), Professor
俄罗斯联邦, Saint Petersburg; Saint PetersburgElizaveta Vasilenko
Saint Petersburg State University
Email: md.vasilenkoea@gmail.com
ORCID iD: 0000-0003-2153-5429
SPIN 代码: 8065-5025
MD, Cand. Sci. (Med.)
俄罗斯联邦, Saint PetersburgEvgeniy Trofimov
North-Western Medical State University named after I.I. Mechnikov
Email: Evgeniy.trofimov@szgmu.ru
ORCID iD: 0000-0003-3236-4485
SPIN 代码: 4358-1663
MD, Dr. Sci. (Med.); assistant professor
俄罗斯联邦, Saint Petersburg参考
- Mazurov VI, Vasilenko EA, et al. Treatment of patients with ankylosing spondilitis — real clinical practice. RMJ. 2019;27(12):37–40. EDN: AWVKEX
- Liew JW, Dubreuil M. Treat to target in axial spondyloarthritis: pros, cons, and future directions. Rheum Dis Clin North Am. 2020;46(2):343–356. doi: 10.1016/j.rdc.2020.01.011
- Karateev AE, Nasonov EL, Yakhno NN, et al. Clinical guidelines «Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice». Modern Rheumatology Journal. 2015;9(1):4–23. EDN: TLJUPZ doi: 10.14412/1996-7012-2015-1-4-23 3
- Gaydukova IZ, Mazurov VI. Spondyloarthritis: approaches to terminology, classification, and diagnotics from V.M. Bekhterev to our days. Therapy. 2019;(8):118–130. EDN: DGFNV doi: 10.18565/therapy.2019.8.118-130 4
- Zhao SS, Robertson S, Reich T, et al. Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis. Rheumatology (Oxford). 2020;59(Suppl 4):iv47–iv57. doi: 10.1093/rheumatology/keaa246
- Lanas A. Boers M, Nuevo J. Gastrointestinal events in at-risk patients starting non-steroidal anti- inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practice. Annals of the Rheumatic Diseases. 2015;74(4):675–681. doi: 10.1136/annrheumdis-2013-204155
- Lanza FL, Chan FK, Quigley EM. Practice parameters committee of the American College of gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728–738. doi: 10.1038/ajg.2009.115
- Fakih O, Desmarets M, Martin B, et al. Impact of NSAIDs on 8-year cumulative incidence of major cardiovascular events in patients with ankylosing spondylitis: a nationwide study. Rheumatology (Oxford). 2023;62(10):3317–3322. doi: 10.1093/rheumatology/kead072
- Rebrov AP, Gaidukova IZ, Poddubnyy DA. Cardiovascular pathology in patients with ankylosing spondylitis. Scientific and Practical Rheumatology. 2012;51(2):100–105. (In Russ.) doi: 10.14412/1995-4484-2012-1281
- Nikiphorou E, Ramiro S, van der Heijde D, et al. Association of comorbidities in spondyloarthritis with poor function, work disability, and quality of life: results from the assessment of spondyloarthritis international society comorbidities in spondyloarthritis study. Arthritis Care Res (Hoboken). 2018;70(8):1257–1262. doi: 10.1002/acr.23468
- Zhao SS, Jones GT, Macfarlane GJ, et al. Association between comorbidities and disease activity in axial spondyloarthritis: results from the BSRBR-AS. Rheumatology (Oxford). 2021;60(7):3189–3198. doi: 10.1093/rheumatology/keaa768
- Mazhar F, Battini V, Pozzi M, et al. Changes in anthropometric parameters after anti-TNFα therapy in inflammatory bowel disease: a systematic review and meta-analysis. Bio Drugs. 2020;34(5): 649–668. doi: 10.1007/s40259-020-00444-9
- Ballegaard C, Skougaard M, Guldberg-Møller J, et al. Comorbidities, pain and fatigue in psoriatic arthritis, psoriasis and healthy controls: a clinical cohort study. Rheumatology (Oxford). 2021;60(7):3289–3300. doi: 10.1093/rheumatology/keaa780
- Shi LH, Lam SH, So H, et al. High inflammatory burden predicts cardiovascular events in patients with axial spondyloarthritis: a long-term follow-up study. Ther Adv Musculoskelet Dis. 2022;14:1759720X221122401. doi: 10.1177/1759720X221122401
- Navarini L, Currado D, Marino A, et al. Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis. Sci Rep. 2022;12(1):7498. doi: 10.1038/s41598-022-11640-8
- Fakih O, Desmarets M, Martin B, et al. Impact of NSAIDs on 8-year cumulative incidence of major cardiovascular events in patients with ankylosing spondylitis: a nationwide study. Rheumatology (Oxford). 2023;62(10):3317–3322. doi: 10.1093/rheumatology/kead072
- Kwon OC, Park MC. Effect of tumor necrosis factor inhibitors on risk of cardiovascular disease in patients with axial spondyloarthritis. Arthritis Res Ther. 2022;24(1):141. doi: 10.1186/s13075-022-02836-4
- González C, Curbelo Rodríguez R, Torre-Alonso JC, et al. Recommendations for the management of comorbidity in patients with axial spondyloarthritis in clinical practice. Reumatol Clin (Engl Ed). 2018;14(6):346–359. doi: 10.1016/j.reuma.2017.03.011
- Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19–34. doi: 10.1136/ard-2022-223296
- Van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the asas-eular management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978–991. doi: 10.1136/annrheumdis-2016-210770
- Verhoeven F, Prati C, Demougeot C, Wendling D. Cardiovascular risk in psoriatic arthritis, a narrative review. Joint Bone Spine. 2020;87(5):413–418. doi: 10.1016/j.jbspin.2019.12.004
- Atzeni F, Gerratana E, Masala IF, et al. Psoriatic arthritis and metabolic syndrome: is there a role for disease modifying anti-rheumatic drugs? Front Med (Lausanne). 2021;8:735150. doi: 10.3389/fmed.2021.735150